Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]

Effect of biologic use on the development of psoriatic arthritis: A population-based study

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately in a probability-based internet panel

Hays RD, Herman PM, Rodriguez A, Slaughter M, Zeng C, Edelen MO. Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately[...]